Orthocell Valuation

Is OCC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OCC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OCC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OCC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OCC?

Key metric: As OCC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for OCC. This is calculated by dividing OCC's market cap by their current revenue.
What is OCC's PS Ratio?
PS Ratio	28.6x
Sales	AU$5.32m
Market Cap	AU$150.64m

OCC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	24.6x
Enterprise Value/EBITDA	-12x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does OCC's PS Ratio compare to its peers?

The above table shows the PS ratio for OCC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	27.1x
RAC Race Oncology	59.4x	34.8%	AU$247.2m
ARX Aroa Biosurgery	3.6x	20.1%	AU$217.3m
PYC PYC Therapeutics	37.9x	15.6%	AU$863.2m
ACW Actinogen Medical	7.4x	20.0%	AU$76.6m
OCC Orthocell	28.6x	n/a	AU$150.6m

Price-To-Sales vs Peers: OCC is expensive based on its Price-To-Sales Ratio (28.6x) compared to the peer average (27.1x).

Price to Sales Ratio vs Industry

How does OCC's PS Ratio compare vs other companies in the AU Biotechs Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap
ARX Aroa Biosurgery	3.6x	20.1%	US$140.28m
IMC Immuron	3.5x	59.7%	US$11.69m
ATH Alterity Therapeutics	4x	25.0%	US$10.30m
BNO Bionomics	2.4x	-5.3%	US$9.52m

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: OCC is expensive based on its Price-To-Sales Ratio (28.6x) compared to the Australian Biotechs industry average (9.7x).

Price to Sales Ratio vs Fair Ratio

What is OCC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OCC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	28.6x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate OCC's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Little Green Pharma

AU$39.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.13

4.2%

-3.8%

Medical Developments International

AU$48.4m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

MVP

AU$0.43

-4.4%

-43.8%

AVITA Medical

US$313.4m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.71

4.8%

-2.4%